HAV Vaccine
Phase 3Vaccine
TakedaHAV Vaccine is one of 32 biologic programs targeting Hepatitis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
237 competitors in Hepatitis
#DrugCompanyPhaseTrials
1Actos
TakedaPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Crestor
AstraZenecaPhase 3
PEG-Intron
Merck & Co.Phase 3
Prevnar
GSKPhase 3
Cervarix
GSKPhase 3
Recombinant Hepatitis B Vaccine
NovartisPhase 3
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Inactivated Hepatitis a Vaccine
Boryung Pharmaceutical Co., LtdPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HAV Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]